Zharov E I, Sukhorukova E S, Sidorenko B A, Sedov V P, Ovcharenko K I
Kardiologiia. 1989 May;29(5):23-7.
Nifangin (nifedipine), manufactured by the Laakepharmos Co., Finland, was used in 75 patients with congestive heart failure due to ischemic heart disease and chronic obstructive bronchitis. The effect of a single 20 mg dose and a course of treatment (60 mg daily for 18 days) was assessed by monitoring with the help of echocardiography, venous occlusion plethysmography, laser Doppler flowmetry as well as external respiration and blood gases partial tension measurement. In patients with chronic obstructive bronchitis, the drug was used in combination with cardiac glycosides and diuretics. A single dose of nifangin reduced regional vascular resistance by 33%, and increased volumetric blood flow rate by 51%. The treatment course increased the stroke index and the cardiac index (by 21 and 23%, respectively) and improved blood oxygenation and external respiration parameters. The absence of side effects makes nifangin one of the most effective vasodilating agents, indicated for patients with congestive heart failure.
芬兰拉克制药公司生产的尼方金（硝苯地平）用于75例因缺血性心脏病和慢性阻塞性支气管炎导致的充血性心力衰竭患者。借助超声心动图、静脉阻塞体积描记法、激光多普勒血流仪以及外呼吸和血气分压测量来评估单次20毫克剂量和一个疗程（每日60毫克，共18天）的效果。在慢性阻塞性支气管炎患者中，该药物与强心苷和利尿剂联合使用。单次剂量的尼方金可使局部血管阻力降低33%，并使容积血流率增加51%。疗程增加了每搏输出指数和心脏指数（分别增加21%和23%），并改善了血液氧合和外呼吸参数。无副作用使尼方金成为最有效的血管扩张剂之一，适用于充血性心力衰竭患者。
